New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
05:55 EDTMMM, MMM, GWW, GWW, UNP, UNP, SWK, SWK, LUV, LUV, RTN, RTN, PCP, PCP, MKC, MKC, LMT, LMT, KEY, KEY, EQT, EQT, DOV, DOV, CELG, CELG, BMY, BMY, BAX, BAX, ABC, ABC, ARG, ARG, XRX, XRXCompanies reporting Before the Market Open on Thursday, January 24
Notable companies reporting before the opening bell on Thursday include 3M Co (MMM), Airgas (ARG), AmerisourceBergen (ABC), Baxter International (BAX), Bristol-Myers Squibb (BMY), Celgene (CELG), Dover (DOV), EQT (EQT), KeyCorp (KEY), Lockheed Martin (LMT), McCormick & Company (MKC), Precision Castparts (PCP), Raytheon (RTN), Southwest Airlines (LUV), Stanley Black & Decker (SWK), Union Pacific (UNP), W.W. Grainger (GWW), and Xerox (XRX).
News For MMM;ARG;ABC;BAX;BMY;CELG;DOV;EQT;KEY;LMT;MKC;PCP;RTN;LUV;SWK;UNP;GWW;XRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
January 21, 2015
10:16 EDTBMYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
08:36 EDTCELGCelgene price target raised to $139 from $115 at RW Baird
Baird raised its price target on Celgene to $139 from $115 following last week's guidance from the company. Baird reiterated its Outperform rating on Celgene shares.
08:30 EDTPCPPrecision Castparts added to US 1 List at BofA/Merrill
Subscribe for More Information
08:07 EDTXRXXerox, Thinfilm announce strategic partnership
Subscribe for More Information
January 20, 2015
16:34 EDTBMYBristol-Myers appoints Giovanni Caforio CEO
Bristol-Myers Squibb announced a number of leadership changes approved by its board of directors and effective at the close of the annual Shareholders’ Meeting on May. Giovanni Caforio, M.D. will become CEO of the company. Lamberto Andreotti will become executive chairman of the board of directors on May 5 and will continue to serve as chairman after his retirement on August 3. James M. Cornelius, 71, has chosen not to stand for re-election as non-executive chairman and will retire from the board. Togo D. West, Jr., 72, will become the lead independent director on the company’s board.
15:36 EDTLUVSouthwest volatility elevated into Q4
Subscribe for More Information
09:02 EDTBAXBaxter receives FDA approval for PHOXILLUM solution
Subscribe for More Information
08:16 EDTBAXMerrimack data of Phase 3 MM-398 NAPOLI-1 study supports development programs
Merrimack Pharmaceuticals (MACK) announced that additional analyses were presented on January 16, 2015 from the Phase 3 NAPOLI-1 study of MM-398, also known as nal-IRI, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Merrimack and Baxter International's (BAX) biopharmaceutical business are collaborating on the development and commercialization of MM-398 outside of the United States and Taiwan. PharmaEngine holds the rights to commercialize MM-398 in Taiwan. Additionally, Merrimack presented preclinical and clinical data from studies of its investigational agents MM-141 and MM-151 in pancreatic and colorectal cancer, respectively. An investigator-sponsored study of MM-398 in colorectal cancer was also presented. The extended analyses for the global NAPOLI-1 Phase 3 trial presented at ASCO GI support the robustness of the overall survival benefit of MM-398 in combination with 5-fluorouracil, or 5-FU, and leucovorin presented in June 2014, at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer, or ESMO GI. The primary analysis, presented at ESMO GI, demonstrated a statistically significant advantage in overall survival with an unstratified hazard ratio of 0.67, and a median of 6.1 months for the combination of MM-398 plus 5-FU and leucovorin compared to 4.2 months in the control arm.
07:43 EDTUNPUnion Pacific weakness creates opportunity, says Bernstein
Subscribe for More Information
07:12 EDTPCPPrecision Castparts price target lowered to $244 from $274 at RBC Capital
Subscribe for More Information
06:39 EDTLUVU.S. airlines may buy back shares amid cheap oil, WSJ reports
Subscribe for More Information
January 18, 2015
16:54 EDTPCPPrecision Castparts looks like a bargain, Barron's says
Precision Castparts looks like a bargain and current levels could be an entry opportunity for long-term investors, Barron's contends in its 'The Trader' column. Reference Link
January 16, 2015
16:29 EDTPCPOn The Fly: Closing Wrap
Subscribe for More Information
12:43 EDTPCPOn The Fly: Midday Wrap
Subscribe for More Information
10:01 EDTPCPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:12 EDTPCPOn The Fly: Pre-market Movers
Subscribe for More Information
09:11 EDTCELGCelgene says oral Otezla approved by European Commission in 2 indications
Celgene International, a wholly-owned subsidiary of Celgene Corporation, announced that the European Commission has granted marketing authorisation for OTEZLA, the company’s oral selective inhibitor of phosphodiesterase 4, in two therapeutic indications: For the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light. Alone or in combination with Disease Modifying Antirheumatic Drugs, for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. The marketing authorization is based on efficacy and safety data from two Phase III programs, ESTEEM AND PALACE, which demonstrate a maintained clinical response among patients with psoriasis and psoriatic arthritis treated with OTEZLA through 52 weeks, across multiple endpoints. The EC decision follows the positive opinion issued by the Committee for Medicinal Products for Human Use in November 2014.12 OTEZLA will be launched in the European Union in the coming months in accordance with local requirements.
09:05 EDTPCPPrecision Castparts downgraded to Hold from Buy at Stifel
Subscribe for More Information
08:29 EDTPCPPrecision Castparts should be bought on weakness, says Wells Fargo
Subscribe for More Information
07:58 EDTPCPPrecision Castparts downgraded to Hold from Buy at Canaccord
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use